

To the Commissioner of Patents and Trademarks, March 21, 2000

In response to the call for public comments on the Revised Utility Examination Guidelines, I personally believe the proposed rules are an improvement on the status quo, but may not go far enough toward protection of access to raw nucleotide sequence. While recognizing that intellectual property rights are central to the investment in and development of the biotechnology and pharmaceutical industries, it is the applications derived from the raw nucleotide sequence that are both marketable and benefit the public health. Raw nucleotide sequence consists of information bundles that in and of itself provide little benefit, do not constitute an invention, are not difficult to generate or clone, particularly in light of recent genomic sequencing, and generally do not meet the utility requirement under Article 35 of the U.S. Code. Nonetheless, as part of the publicly funded effort to sequence the human genome, I understand how valuable the sequence data is. To limit patentability and therefore utility requirements to applications brings maximum benefit to both academic researchers and industry in terms of insuring unfettered access to the cornerstone knowledge necessary to advance biomedical research and therapeutics. Also, the DNA sequence data is information not an invention. As such, information in whatever form it takes should not be patentable. Finally, and perhaps more controversially, I believe that at least human genomic sequence goes to the core of what it means to be human and no individual or corporation should control or have ownership of something so basic.

Yours sincerely,

Glenn Haller
Asst. Dir. of Bioinformatics
Dept. of Molecular and Human Genetics
Human Genome Sequencing Center
Baylor College of Medicine
One Baylor Plaza, Rm. N1419.05
Houston, TX 77030
Ph. 713-798-3124
Fax 713-798-5741
[ghaller <mailto:ggghaller@bcm.tmc.edu>@bcm.tmc.edu](mailto:ggghaller@bcm.tmc.edu)